Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06932757 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Quisinostat in High-Risk Uveal Melanoma
A Phase 2 study of Uveal Melanoma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT06932757 is a Phase 2 study of Uveal Melanoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 63 participants, below the 143-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06932757, a Phase 2 study of Uveal Melanoma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
Conditions Studied
Interventions
- DRUG Quisinostat
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2030-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06932757
The ClinicalTrials.gov registry entry for NCT06932757 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (56% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Quisinostat is the first listed.
NCT06932757 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06932757 about?
NCT06932757 is a clinical study titled "Adjuvant Quisinostat in High-Risk Uveal Melanoma". The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
What is the current status of trial NCT06932757?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2025-05-27. Estimated completion is 2030-05-27.
What conditions does trial NCT06932757 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT06932757?
The interventions under investigation include: Quisinostat (DRUG).
Who is sponsoring clinical trial NCT06932757?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06932757 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.